Menu Search
Equities

Terumo Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TUO:FRA

Terumo Corp

Actions
  • Price (EUR)10.30
  • Today's Change-0.50 / -4.63%
  • Shares traded200.00
  • 1 Year change-40.46%
  • Beta1.0521
Data delayed at least 15 minutes, as of Feb 16 2026 07:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Terumo Corp is a Japan-based company mainly engaged in the manufacture and sale of medical devices and pharmaceuticals. The Company operates in three segments. The Cardiovascular Company segment provides guidewires for angiography, catheters for angiography, introducer sheaths, coils, stents and bag embolization devices for treatment of cerebral aneurysms, artificial lungs and artificial heart-lung machines. The Medical Care Solutions Company segment provides hospital care solutions, life care solutions, and pharmaceutical solutions. The Blood and Cell Technology Company segment provides blood bags, component blood collection systems, automated blood product systems, pathogen reduction systems, and centrifugal blood component separators.

  • Revenue in JPY (TTM)1.10tn
  • Net income in JPY127.90bn
  • Incorporated1921
  • Employees30.69k
  • Location
    Terumo Corp2-44-1, HatagayaSHIBUYA-KU 151-0072JapanJPN
  • Phone+81 333748111
  • Fax+81 333748399
  • Websitehttps://www.terumo.co.jp
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4543:TYO since
announced		Transaction
value
OrganOx LtdDeal completed24 Aug 202524 Aug 2025Deal completed-29.58%1.50bn
WuXi Biologics (Cayman) Inc-Drug Product (DP) PlantDeal completed14 May 202514 May 2025Deal completed-30.74%167.76m
Data delayed at least 15 minutes, as of Feb 17 2026 04:38 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.